Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • May 7, 2009

166_ip_2009-05-07_6c7ad3c5-9706-4033-b232-97e9813e766c.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Analyst Meeting – Q1/09 Results

April 30, 2009

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Fresenius Group: Financial Results

S
l
a
e
s		 E
B
I
T		 i
*
N
t
e
n
c
o
m
e
/
Q
1
0
9		 €
3
3
7
3
m
,		 €
4
7
7
m		 €
1
1
0
m
G
h
t
t
t
t
r
o
w
a
c
o
n
s
a
n
t
c
u
r
r
e
n
c
y
r
a
e
s		 %
1
5		 2
0
%		 6
%
G
h
l
t
t
t
o
a
a
c
a
r
w
u
t
e
n
e
c
u
r
r
c
y
r
a
s		 2
1
%		 2
7
%		 1
0
%

* Net income attributable to Fresenius SE and before special items due to MEB and CVR accounting

Fresenius Group: Significant Growth in All Business Segments

Q
/
0
9
1		 F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 F
i
r
e
s
e
n
u
s
K
b
i
a		 F
i
r
e
s
e
n
u
s
H
l
i
e
o
s		 F
i
r
e
s
e
n
u
s
V
d
a
m
e
l
S
a
e
s
h
G
t
o
r
w		 \$
U
S
2
5
6
0
m
,
2
%		 €
7
2
2
m
3
2
%		 €
5
7
7
m
1
3
%		 €
1
1
6
m
%
5
7
E
B
I
T
h
G
t
o
r
w		 \$
U
S
3
9
6
m
2
%		 €
1
3
8
m
5
9
%		 €
4
4
m
1
6
%		 €
4
m
0
%

Fresenius Kabi: Update Q1/09

  • Strong organic sales growth of 7 % (excluding APP und Dabur Pharma)
  • APP Pharmaceuticals with 30 % sales growth in local currency
  • Continued double-digit organic sales growth in emerging markets
  • Roll-out of Dabur's oncology portfolio → USA: Irinotecan, Paclitaxel, Epirubicin → Europe: Irinotecan, Paclitaxel, Epirubicin, Gemcitabine

Fresenius Helios: Update Q1/09

  • Strong organic like-for-like sales growth of 5 %
  • Krefeld/Huels hospital expected to achieve positive EBIT in 2009
  • Integration of newly acquired hospitals in Northeim and Mansfeld on track
  • Election year 2009: favorable reimbursement legislation but slow privatization activity HELIOS hospital Hettstedt (Mansfeld)

Fresenius Vamed: Update Q1/09

Significant sales growth driven by strong project business

EBIT within target expectations

Favorable order intake expected to continue

Q Q Q Q
/ / / /
0 0 0 0
6 1 8 9
1 7 1 1
9
4		 6
6		 2
1
5		 8
8		 €
m

Fresenius Biotech: Removab – First Approved Trifunctional Antibody Worldwide

  • European Commission approved Removab for the treatment of malignant ascites
  • Market launch in Germany within a few weeks; further European countries to follow
  • List price Germany: € 11,500 per treatment (four doses of 10, 20, 50 and 150 µg)

Group Financials Q1/09 −Outlook 2009

Fresenius Group: Profit and Loss Statement, Adjusted for Special Items

€
m		 /
Q
0
9
1		 /
Q
0
8
1		 Y
l
t
a
c
a
u
t
r
a
e
s		 Y
o
t
t
c
o
n
s
a
n
t
r
a
e
s		 R
k
e
m
a
r
s
l
S
a
e
s		 3
3
7
3
,		 2
7
9
8
,		 2
1
%		 1
5
%		 h
O
i
8
%
t
r
g
a
n
c
g
r
o
w
:
E
B
I
T		 4
7
7		 3
7
7		 2
%
7		 2
0
%		 l.
€
I
7
n
c
m
i
i
f
t
t
A
P
P
a
m
o
r
z
a
o
n
o
i
i
b
l
t
t
n
a
n
g
e
a
s
s
e
s
l
I
t
t
t
n
e
e
s
e
s
r
r
u		 1
4
5
-		 8
4
-		 7
3
%
-		 6
7
%
-
T
a
x
e
s		 1
1
1
-		 1
0
3
-		 8
%
-		 1
%
-		 3
3
%
T
t
4
a
x
r
a
e
:
*
N
i
t
e
n
c
o
m
e		 1
1
0		 1
0
0		 1
0
%		 6
%

*Net income attributable to Fresenius SE and before special items due to MEB and CVR accounting

Fresenius Kabi: Organic Sales Growth Fully in Line with Expectations

€
m		 Q
/
1
0
9		 Q
/
1
0
8		 O
i
r
g
a
n
c
G
h
t
r
o
w
f
h
i
I
T
n
s
o
n
e
a
p
u
r
y		 6
8
1		 1
7
5		 %
4
I
V
D
g
s
r
u		 2
3
7		 7
5		 1
1
%
(
lu
d
ing
A
P
P
d
Da
bu
)
ex
c
an
r
l
l
C
i
i
N
i
i
t
t
n
c
a
u
r
o
n		 2
1
6		 1
9
8		 1
0
%
d
l
/
M
i
D
i
e
c
a
e
v
c
e
s
f
h
l
T
i
T
a
n
s
s
o
n
e
c
n
o
o
g
r
u
y		 1
0
1		 9
7		 5
%
l
l
T
t
o
a
s
a
e
s		 7
2
2		 5
4
5		 7
%

Fresenius Kabi: Strong EBIT Growth

€
m		 Q
/
1
0
9		 Q
/
1
0
8		 G
h
t
r
o
w
E
o
p
e
u
r
M
i
a
r
g
n		 8
0
2
1
3
%		 8
0
2
1
7
%		 0
%
h
i
N
t
A
o
m
e
c
a
r
r
M
i
a
r
g
n		 0
5
2
9
8
%		 3
0
0
%
1		 -
-
f
/
/
f
A
i
P
i
i
L
i
A
i
A
i
t
s
a
a
c
c
a
n
m
e
r
c
a
r
c
a
-
M
i
a
r
g
n		 2
7
1
5
2
%		 2
3
1
5
6
%		 %
1
7
d
C
C
R
&
D
t
t
o
p
o
a
e
a
n
o
p
o
a
e
r
r
r
r		 1
9
-		 1
9
-		 0
%
T
l
E
B
I
T
t
o
a		 1
3
8		 8
7		 5
9
%
M
i
a
r
g
n		 %
1
9
1		 %
1
6
0

Fresenius Helios: Excellent Sales and Earnings Development

€
m		 /
Q
0
9
1		 /
Q
0
8
1		 G
h
t
r
o
w
T
l
l
t
o
a
s
a
e
s		 5
7
7		 5
0
9		 3
%
1
E
B
I
T
b
l
h
d
l
f
l
i
i
i
i
E
t
t
s
a
s
e
c
n
c
p
o
o
o
r
M
i
a
g
n
r		 4
4
8
2
%		 8
3
%
7
5		 1
6
%
i
i
i
N
t
t
e
a
c
q
s
o
n
s
u
(
l
d
/
d
l
d
)
i
i
i
i
1
t
t
o
n
o
o
n
e
o
n
o
o
n
<
c
s
a
c
s
a
y
r		 0 0
T
l
E
B
I
T
t
o
a		 4
4		 3
8		 1
6
%
M
i
a
r
g
n		 7
6
%		 7
5
%

Fresenius Vamed: Strong Sales Growth

€
m		 /
Q
1
0
9		 /
Q
1
0
8		 C
h
a
n
g
e
b
P
j
i
t
o
e
c
s
n
e
s
s
r
u
S
b
i
i
e
r
v
c
e
u
s
n
e
s
s		 6
8
4
8		 3
5
3
9		 9
%
4
2
3
%
l
l
T
t
o
a
s
a
e
s		 1
1
6		 7
4		 %
5
7
T
l
E
B
I
T
t
o
a
M
i
a
r
g
n		 4
%
3
4		 4
5
4
%		 0
%
1
d
O
i
k
t
r
e
r
n
a
e		 8
8		 1
2
5		 %
3
0
-
1
O
d
b
k
l
r
e
r
a
c
o
g		 9
2
5		 2
5
7
1		 %
4

1Project business only 2 Dec 31, 2008

Fresenius Group: Cash Flow

€
m		 Q
/
1
0
9		 Q
/
1
0
8		 Y
Y
o		 k
R
e
m
a
r
s
h
f
l
C
a
s
o
w		 4
0
9		 3
0
0		 3
6
%
C
h
i
k
i
i
l
t
a
n
g
e
n
w
o
r
n
g
c
a
p
a		 1
3
7
-		 2
2
-		 --
h
k
k
C
i
t
t
a
n
g
e
n
m
a
o
-m
a
e
r
r
-
l
d
i
M
E
B
C
V
R
t
a
a
o
n
a
n
v
u		 5
4
-		 0 --
O
i
C
h
f
l
t
p
e
r
a
n
g
a
s
o
w		 8
1
2		 2
8
7		 3
%
5
-		 M
i
5
4
%
a
g
n
r
:
C
(
)
t
a
p
e
x
n
e		 1
4
7
-		 1
6
1
-		 9
%
C
h
f
l
a
s
o
w
(
b
f
d
d
d
d
)
i
i
i
i
i
t
e
o
e
a
c
q
s
o
n
s
a
n
e
n
s
r
u
v		 3
5		 1
1
7		 %
7
0
-
A
i
i
t
i
(
)
t
c
q
u
s
o
n
s
n
e		 8
6
-		 9
1
5
-		 6
%
4
d
d
D
i
i
e
n
s
v		 1
1
-		 5
-		 1
2
0
%
-
h
f
l
F
C
r
e
e
a
s
o
w
(
f
i
i
i
d
d
i
i
d
d
)
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 2
6
-		 4
7
-		 3
2
%
-

Fresenius Group: 2009 Financial Outlook Confirmed

2
0
0
9
O
l
k
t
u
o
o
F
i
r
e
s
e
n
s
u
b
i
K
a		 S
l
h
t
a
e
s
g
r
o
w
*
E
B
I
T
i
m
a
g
n
r		 2
3
0
%
5
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y
–
1
9
5
2
0
5
%
–
F
i
r
e
s
e
n
u
s
l
i
H
e
o
s		 l
S
a
e
s
E
B
I
T		 b
€
2
3
>
n
€
1
8
0
2
0
0
m
–
F
i
r
e
s
e
n
s
u
d
V
a
m
e		 S
l
h
t
a
e
s
g
r
o
w
h
E
B
I
T
t
g
o
r
w		 0
%
5
1
–
5
1
0
%
–
F
i
r
e
s
e
n
s
u
B
i
h
t
o
e
c		 E
B
I
T		 €
0
0
4
5
m
-
–
-

* Translation effects may impact Fresenius Kabi's margin as APP provides a significant earnings contribution from the US\$ area. This guidance is based on the US\$/€ exchange rate from the beginning of 2009.

Fresenius Group: Positive Outlook 2009 Confirmed

G
i
d
2
0
0
9
a
n
c
e
u
h
R
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y
i
o
g
n
r
a
c		 1
0
%
>
6
8
%
–
h
*
N
i
t
t
e
n
c
o
m
e
g
o
r
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 0
1
%
~
C
a
p
e
x		 €
0
0
0
7
7
5
m
~
–

*Net income attributable to Fresenius SE and before special items due to MEB and CVR accounting

Attachments

Special items

    • Other financial result:
  • CVR (Contingent Value Right): The trading price of the CVR on the B/S date is considered as fair redemption value. Changes of this value are recognized in the P&L. Valuation changes will lead to quarterly gains or expenses until maturity. Calculation as of March 31, 2009: Δ between trading price of US\$ 0.35 at December 31,2008 and trading price at March 31, 2009 of US\$ 0.37 multiplied by 163.3 million CVRs = US\$ 3.3 million = € 3 million.
  • MEB (Mandatory Exchangeable Bond): Mark-to-market accounting based on the Black-Scholes valuation model reflecting FMC's share price. Any change in fair value is recognized in the P&L. Valuation changes will lead to gains or expenses until maturity.

Fresenius Group: Overview – Calculation of Noncontrolling Interest

€
m		 /
Q
1
0
9		 /
F
Y
0
8
f
b
d
l
l
E
i
i
i
t
t
t
t
a
n
n
g
s
e
o
e
a
a
n
n
o
n
o
n
o
n
g
n
e
e
s
r
r
x
c
r
r		 0
9
4		 1
1
1
4
,
T
a
e
s
x		 1
3
4
-		 0
4
4
-
l
l
h
f
N
i
i
t
t
t,
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s
e
r
e
o		 1
1
1
-		 4
0
4
-
d
l
F
i
M
i
C
i
t
t
e
s
e
n
s
e
c
a
a
e
n
e
n
c
o
m
e
n
o
r
u
r
i
b
b
l
i
(
6
%
)
t
t
t
t
F
4
a
r
u
a
e
o
r
e
s
e
n
u
s
~		 9
7
-		 3
5
6
-
l
l
h
l
d
d
l
N
i
i
i
F
i
M
i
t
t
t
o
n
c
o
n
o
n
g
n
e
e
s
o
e
s
n
e
s
e
n
s
e
c
a
r
r
r
r
u
C
(
/
2
0
0
8
S
\$
2
9
Q
/
2
0
0
9
S
\$
8
d
F
Y
U
1
U
i
a
r
e
:
m
:
m
a
c
c
o
r
n
g
,
d
l
's
l
)
F
i
M
i
C
F
i
i
S
t
t
t
t
o
e
s
e
n
s
e
c
a
a
e
n
a
n
c
a
a
e
m
e
n
s
r
u
r		 6
-		 2
0
-
l
l
h
l
d
b
N
i
i
i
F
i
K
i,
t
t
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
a
F
i
H
l
i
F
i
B
i
h
d
d
t
e
e
n
e
o
e
e
n
o
e
n
e
r
s
u
s
s
r
s
u
s
c
a
u
,
d
's
2
3
%
l
h
F
i
V
i
t
t
o
r
e
s
e
n
u
s
a
m
e
e
x
e
r
n
a
o
w
n
e
r
s
p		 8
-		 2
8
-
b
b
l
N
i
i
F
i
S
E
t
t
t
t
t
e
n
c
o
m
e
a
a
e
o
e
s
e
n
s
r
u
r
u		 1
6
4		 2
7
0

Fresenius Group: Debt Maturity Profile 1March 31, 2009

1 Based on utilization of major financing instruments; excl. Fresenius Medical Care's Accounts Receivable Facility 2Major part already refinanced (maturity 2012/2014)

Fresenius Group: Debt and Interest Ratios

Debt excludes Mandatory Exchangeable Bonds

* Pro forma APP acquisition and before special items

Fresenius Kabi: Organic Sales Growth Fully in Line with Expectations

€
m		 /
Q
1
0
9		 /
Q
1
0
8		 O
i
r
g
a
n
c
G
h
*
t
r
o
w
E
o
p
e
u
r		 3
6
7		 3
6
8		 %
5
h
N
A
i
t
o
r
m
e
r
c
a		 6
8
1		 3
0		 3
%
f
A
i
P
i
i
s
a
a
c
c
-		 1
1
1		 8
6		 1
0
%
f
/
L
i
A
i
A
i
t
a
n
m
e
a
a
r
c
r
c		 6
7		 6
1		 2
0
%
T
l
l
t
o
a
s
a
e
s		 7
2
2		 5
4
5		 7
%

* excluding APP Pharmaceuticals and Dabur Pharma

Fresenius Helios: Strong Sales Growth

€
m		 /
Q
0
9
1		 /
Q
0
8
1		 G
h
t
r
o
w
b
l
h
d
l
f
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o		 3
6
5		 0
5
4		 *
%
5
A
i
i
i
t
c
q
s
o
n
s
(
l
d
)
u
i
t
i
1
<
c
o
n
s
o
a
o
n
y
r		 4
1
D
i
i
t
t
v
e
s
u
r
e
s
(
d
l
i
d
i
1
)
t
<
e
c
o
n
s
o
a
o
n
y
r		 5
T
l
l
t
o
a
s
a
e
s		 5
7
7		 5
0
9		 %
1
3

Fresenius Helios: Performance Indicators

Q
/
1
0
9		 Q
/
1
0
8		 C
h
a
n
g
e
1
f
h
l
N
i
t
o
o
o
s
p
a
s
l
A
i
i
t
c
e
c
n
c
s
u
-
l
P
i
i
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 6
2
4
3
1
9		 5
7
3
8
1
9
1
f
b
d
N
o
o
e
s
l
i
i
A
t
c
u
e
c
n
c
s
-
l
P
t-
t
i
i
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 8
9
2
1
4
,
0
6
1
5
4
,
3
6
4
4
,		 2
9
1
7
4
,
3
3
3
1
7
,
3
6
5
1
,		 7
%
0
%
1
2
%
-
2
d
A
i
i
m
s
s
o
n
s
(
)
A
i
i
t
t
t
c
e
c
a
e
n
-p
a
e
n
u
r
-		 1
4
7
6
2
3
,		 1
2
7
1
1
7
,		 1
6
%
2
O
c
c
u
p
a
n
c
y
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 9
%
7		 %
7
7
2
l
h
f
(
d
)
A
t
t
e
a
g
e
e
n
g
o
s
a
a
s
v
r
y
y
3
A
t
e
e
c
u
c
a
r
-
3
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 7
0
3
0
5		 7
1
3
0
1

1Dec 31, 2008 2 Clinics in Germany 3 2008 cumulated

Fresenius Helios:Sales Impact Hospital Acquisitions

(Lower Saxony) (Saxony Anhalt)

Divestitures

transferred to VAMED

Acquisitions Annualized sales

  • Hospital Mariahilf, Hamburg € ~26 m consolidated as of Aug 1, 2008
  • 2 hospitals Northeim County € ~50 m consolidated as of Jan 1, 2009
  • 3 hospitals Mansfeld-Südharz € ~86 m consolidated as of Jan 1, 2009

4 hospitals in Czech Republic € ~24 m deconsolidated as of Oct 1, 2008

Fresenius Group: Key Figures According to IFRS

€
m		 /
Q
9
1
0
S
G
U
A
A
P		 /
Q
9
1
0
S
I
F
R
l
S
a
e
s		 3
3
7
3
,		 3
3
7
3
,
E
B
I
T		 4
7
7		 4
7
4
l
I
t
t
t
n
e
e
s
e
s
r
r
u		 1
4
5
-		 1
4
5
-
*
N
i
t
e
n
c
o
m
e		 1
6
4		 1
6
1
i
d
j
d


N
t
t
e
n
c
o
m
e
a
s
e
u
,		 0
1
1		 0
1
7
h
f
l
O
i
C
t
p
e
r
a
n
g
a
s
o
w		 1
8
2		 1
8
3
l
h
l
B
t
t
t
a
a
n
c
e
s
e
e
o
a		 2
3
1
5
7
,		 2
1
8
3
5
,

* Net income attributable to Fresenius SE **Net income attributable to Fresenius SE before special items due to MEB and CVR accounting

Financial Calendar

  • 8.5.2009 Annual General Meeting, Frankfurt/Main
  • 11.5.2009 Payment of Dividend*
  • 4.8.2009 Report on 1st half 2009
  • 3.11.2009 Report on 1st-3rd quarters 2009

Contact

  • Birgit Grund SVP Investor Relations Fresenius SE
  • Telephone: +49 6172 608-2485 e-mail:[email protected]

For further information and current news: http://www.fresenius.com

* Subject to approval by the AGM

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.